Author: admin

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Lung Disease Market Forecast

Some of the key facts of the Interstitial Lung Disease Market Report:

• The Interstitial Lung Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In February 2025, Boehringer Ingelheim’s lung disease treatment, nerandomilast, has achieved success in a Phase III trial, positioning the company to pursue approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD study (NCT05321082) indicate that nerandomilast enhanced lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, the company conducted a separate IPF trial, which contributed to its new drug application (NDA) submission last year.

• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

• The Interstitial Lung Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Lung Disease pipeline products will significantly revolutionize the Interstitial Lung Disease market dynamics.

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) is a broad term that refers to a group of lung disorders characterized by inflammation and scarring (fibrosis) of the interstitium, which is the tissue that surrounds and supports the air sacs (alveoli) in the lungs. This inflammation and scarring can impair the ability of the lungs to function properly, leading to symptoms such as cough, shortness of breath, and decreased exercise tolerance.

Get a Free sample for the Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/interstitial-lung-disease-market

Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Lung Disease Epidemiology Segmentation:

The Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Interstitial Lung Disease

• Prevalent Cases of Interstitial Lung Disease by severity

• Gender-specific Prevalence of Interstitial Lung Disease

• Diagnosed Cases of Episodic and Chronic Interstitial Lung Disease

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ Interstitial Lung Disease Epidemiology Forecast

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Interstitial Lung Disease Therapies and Key Companies

• J2H P1905: J2H Biotech

• CR405: Crystec Pharma

• APT-101: Apie Therapeutics

• BLR-200: BLR Bio

• M-156: ImmunoMet Therapeutics

• AD-214: AdAlta Limited

• Vixarelimab: Genentech

• Abatacept: Bristol-Myers Squibb

• HEC585: Sunshine Lake Pharma

• Efzofitimod: aTyr Pharma

• Pamrevlumab: FibroGen

• BI-1015550: Boehringer Ingelheim

Discover more about therapies set to grab major Interstitial Lung Disease market share @ Interstitial Lung Disease Treatment Landscape

Interstitial Lung Disease Market Drivers

• Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

Interstitial Lung Disease Market Barriers

• However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

Scope of the Interstitial Lung Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies

• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Interstitial Lung Disease Market Access and Reimbursement

To know more about Interstitial Lung Disease companies working in the treatment market, visit @ Interstitial Lung Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Interstitial Lung Disease

3. SWOT analysis of Interstitial Lung Disease

4. Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Interstitial Lung Disease Market Overview at a Glance

6. Interstitial Lung Disease Disease Background and Overview

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Lung Disease

9. Interstitial Lung Disease Current Treatment and Medical Practices

10. Interstitial Lung Disease Unmet Needs

11. Interstitial Lung Disease Emerging Therapies

12. Interstitial Lung Disease Market Outlook

13. Country-Wise Interstitial Lung Disease Market Analysis (2019–2032)

14. Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Interstitial Lung Disease Market Drivers

16. Interstitial Lung Disease Market Barriers

17. Interstitial Lung Disease Appendix

18. Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Lung Disease Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta

The Endocarditis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endocarditis pipeline products will significantly revolutionize the Endocarditis market dynamics.

DelveInsight’s “Endocarditis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Endocarditis, historical and forecasted epidemiology as well as the Endocarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Endocarditis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Endocarditis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endocarditis Market Forecast

Some of the key facts of the Endocarditis Market Report:

• The Endocarditis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• Endocarditis is an uncommon infection in the US; over 25% of cases affect people aged 60 years or above. Yet, it is also the fourth most common life-threatening infection after sepsis, pneumonia, and intra-abdominal abscess, with an estimated inpatient mortality rate between 15 and 30%.

• According to the National Organisation for Rare Disorders (NORD, n.d.) Infective endocarditis appears to be approximately twice as common in men as women. In the past, disease onset occurred at an average age of 35.

• Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

• Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

• The Endocarditis epidemiology based on gender analyzed that endocarditis affects males and females in a ratio of 2:1

Endocarditis Overview

Endocarditis is defined as an inflammation of the endocardial surface of the heart. This may include heart valves, mural endocardium or the endocardium that covers prosthetic valves, pacemaker/defibrillator leads, and catheters. Infective and non-infective-related causes of endocarditis must be distinguished. The inflammation is related to a bacterial or fungal infection in most cases. Approximately 80% of infective endocarditis cases are caused by the bacteria streptococci and staphylococci.

Get a Free sample for the Endocarditis Market Report:

https://www.delveinsight.com/report-store/endocarditis-market

Endocarditis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endocarditis Epidemiology Segmentation:

The Endocarditis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Endocarditis

• Prevalent Cases of Endocarditis by severity

• Gender-specific Prevalence of Endocarditis

• Diagnosed Cases of Episodic and Chronic Endocarditis

Download the report to understand which factors are driving Endocarditis epidemiology trends @ Endocarditis Epidemiological Insights

Endocarditis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endocarditis market or expected to get launched during the study period. The analysis covers Endocarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endocarditis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endocarditis Therapies and Key Companies

• Tonabacase (LSVT-1701): Lysovant

• Exebacase(CF-301): ContraFect

• ContraFect: Basilea Pharmaceuticals

• daptomycin: Cubist Pharmaceuticals

• Ceftobiprole medocaril: Basilea Pharmaceutica

• Daptomycin: Merck Sharp & Dohme

To know more about Endocarditis treatment, visit @ Endocarditis Medications

Scope of the Endocarditis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Endocarditis Companies: Lysovant, ContraFect, Basilea Pharmaceuticals, Cubist Pharmaceuticals, Basilea Pharmaceutica, Merck Sharp & Dohme, and others

• Key Endocarditis Therapies: Tonabacase (LSVT-1701), Exebacase(CF-301), ContraFect, daptomycin, Ceftobiprole medocaril, Daptomycin, and others

• Endocarditis Therapeutic Assessment: Endocarditis current marketed and Endocarditis emerging therapies

• Endocarditis Market Dynamics: Endocarditis market drivers and Endocarditis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Endocarditis Unmet Needs, KOL’s views, Analyst’s views, Endocarditis Market Access and Reimbursement

Discover more about therapies set to grab major Endocarditis market share @ Endocarditis Treatment Landscape

Table of Contents

1. Endocarditis Market Report Introduction

2. Executive Summary for Endocarditis

3. SWOT analysis of Endocarditis

4. Endocarditis Patient Share (%) Overview at a Glance

5. Endocarditis Market Overview at a Glance

6. Endocarditis Disease Background and Overview

7. Endocarditis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endocarditis

9. Endocarditis Current Treatment and Medical Practices

10. Endocarditis Unmet Needs

11. Endocarditis Emerging Therapies

12. Endocarditis Market Outlook

13. Country-Wise Endocarditis Market Analysis (2020–2034)

14. Endocarditis Market Access and Reimbursement of Therapies

15. Endocarditis Market Drivers

16. Endocarditis Market Barriers

17. Endocarditis Appendix

18. Endocarditis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endocarditis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Lysovant, ContraFect, Basilea Pharmaceuticals

The Unstable Angina market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Unstable Angina pipeline products will significantly revolutionize the Unstable Angina market dynamics.

DelveInsight’s “Unstable Angina Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Unstable Angina, historical and forecasted epidemiology as well as the Unstable Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Unstable Angina market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Unstable Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Unstable Angina Market Insights

Some of the key facts of the Unstable Angina Market Report:

• The Unstable Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In November 2024, Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator aimed at lowering the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast-based procedures like percutaneous coronary intervention (PCI). In the US, over one million PCI procedures are performed annually on patients with unstable angina, with around half having additional health conditions that affect PCI safety. This represents a significant unmet medical need, as no FDA-approved treatments currently exist to prevent or manage AKI and MACKE. Saghmos Therapeutics is partnering with the Duke Clinical Research Institute to refine and execute the Phase 3 trial for ST-62516.

• Coronary heart disease (CHD) impacts over 17 million adults in the United States. Of the 17 million Americans affected, 55% of those are male. Angina affects 10 million people in the United States

• According to the study of Nathan Messas, Unstable Angina or Angina pectoris is the most prevalent manifestation of myocardial ischemia and coronary artery disease (CAD), affecting up to 9 million patients in the United States

• Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

• Key Unstable Angina Therapies: T89, AR36, and others

• The Unstable Angina epidemiology based on gender analyzed that it can be concluded that Unstable Angina is more common in males than female

Unstable Angina Overview

Unstable angina is a type of chest pain that occurs suddenly and unpredictably due to reduced blood flow to the heart. It is a medical emergency and a warning sign of an impending heart attack. Unlike stable angina, it can occur at rest, lasts longer, and may not be relieved by medication or rest. It results from the rupture of a plaque in the coronary artery, leading to partial blockage. Immediate treatment is essential to restore blood flow and prevent heart damage.

Get a Free sample for the Unstable Angina Market Report:

https://www.delveinsight.com/report-store/unstable-angina-market

Unstable Angina Market

The dynamics of the Unstable Angina market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The emerging pipeline for the treatment of Unstable Angina have few candidates. These products are in mid or last stage of investigation. With the launch of emerging therapies the total market of Unstable Angina is supposed to experience immense changes in the future”

Unstable Angina Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Unstable Angina Epidemiology Segmentation:

The Unstable Angina market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Unstable Angina

• Prevalent Cases of Unstable Angina by severity

• Gender-specific Prevalence of Unstable Angina

• Diagnosed Cases of Episodic and Chronic Unstable Angina

Download the report to understand which factors are driving Unstable Angina epidemiology trends @ Unstable Angina Epidemiological Insights

Unstable Angina Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Unstable Angina market or expected to get launched during the study period. The analysis covers Unstable Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Unstable Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Unstable Angina Therapies and Key Companies

• T89: Tasly Pharmaceuticals

• AR36: Arbor Pharmaceuticals

To know more about Unstable Angina treatment, visit @ Unstable Angina Medications

Scope of the Unstable Angina Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others

• Key Unstable Angina Therapies: T89, AR36, and others

• Unstable Angina Therapeutic Assessment: Unstable Angina current marketed and Unstable Angina emerging therapies

• Unstable Angina Market Dynamics: Unstable Angina market drivers and Unstable Angina market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Unstable Angina Unmet Needs, KOL’s views, Analyst’s views, Unstable Angina Market Access and Reimbursement

Discover more about therapies set to grab major Unstable Angina market share @ Unstable Angina Treatment Landscape

Table of Contents

1. Unstable Angina Market Report Introduction

2. Executive Summary for Unstable Angina

3. SWOT analysis of Unstable Angina

4. Unstable Angina Patient Share (%) Overview at a Glance

5. Unstable Angina Market Overview at a Glance

6. Unstable Angina Disease Background and Overview

7. Unstable Angina Epidemiology and Patient Population

8. Country-Specific Patient Population of Unstable Angina

9. Unstable Angina Current Treatment and Medical Practices

10. Unstable Angina Unmet Needs

11. Unstable Angina Emerging Therapies

12. Unstable Angina Market Outlook

13. Country-Wise Unstable Angina Market Analysis (2019–2032)

14. Unstable Angina Market Access and Reimbursement of Therapies

15. Unstable Angina Market Drivers

16. Unstable Angina Market Barriers

17. Unstable Angina Appendix

18. Unstable Angina Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unstable Angina Market on Track for Major Expansion by 2032, According to DelveInsight | Tasly Pharmaceuticals, Arbor Pharmaceuticals

DelveInsight’s “Portal Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Portal Hypertension, historical and forecasted epidemiology as well as the Portal Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Portal Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Portal Hypertension Market Forecast

Some of the key facts of the Portal Hypertension Market Report:

• The Portal Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company specializing in innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), today reported encouraging two-year outcomes from the open-label compensated MASH cirrhosis (F4c) cohort of the Phase 3 MAESTRO-NAFLD-1 trial evaluating Rezdiffra. The 122 patients enrolled showed notable improvements from baseline in liver stiffness, liver fat content, fibrosis biomarkers, liver volume, and clinically significant portal hypertension (CSPH) risk scores.

• Around 2000 Americans per 100,000 have liver cirrhosis in the United States, and more than 90% of those who have cirrhosis go on to develop portal hypertension, according to National Institutes of Health (n.d.)

• Although it is likely similar to that of the US, the international incidence of portal hypertension is similarly unknown, with variances mostly in the underlying reasons. The major causes of portal hypertension and esophageal varices in Western countries are alcoholic and viral cirrhosis; at the time of diagnosis, gastroesophageal varices are present in 30% of patients with compensated cirrhosis and 60–70% of patients with decompensated cirrhosis

• Portal hypertension, a disease that precedes the bulk of cirrhotic patients’ deaths, eventually develops in about 90% of cirrhotic patients

• Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

• Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

• The Portal Hypertension epidemiology based on gender analyzed that portal hypertension affects males slightly more than females

• The Portal Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Portal Hypertension pipeline products will significantly revolutionize the Portal Hypertension market dynamics.

Portal Hypertension Overview

A rise in the pressure inside the portal vein, which conducts blood from the digestive system to the liver, is known as portal hypertension. A obstruction in the blood flow through the liver is the root cause of the rise in pressure. Large veins (varices) grow across the oesophagus and stomach to get past the blockage as a result of increased pressure in the portal vein. The varices deteriorate and become more prone to bleeding.

Get a Free sample for the Portal Hypertension Market Report

https://www.delveinsight.com/report-store/portal-hypertension-market

Portal Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Portal Hypertension Epidemiology Segmentation:

The Portal Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Portal Hypertension

• Prevalent Cases of Portal Hypertension by severity

• Gender-specific Prevalence of Portal Hypertension

• Diagnosed Cases of Episodic and Chronic Portal Hypertension

Download the report to understand which factors are driving Portal Hypertension epidemiology trends @ Portal Hypertension Epidemiology Forecast

Portal Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Portal Hypertension market or expected to get launched during the study period. The analysis covers Portal Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Portal Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Portal Hypertension Therapies and Key Companies

• BI 685509: Boehringer Ingelheim

• GR-MD-02: Galectin Therapeutics Inc.

• Sorafenib: Onyx Therapeutics, Inc.

• Serelaxin: Novartis

• Ifetroban: Cumberland Pharma

• IDN-6556: Conatus Pharma

• Terlipressin: Ferozsons Laboratories Ltd.

• Emricasan: Histogen

• Ambrisentan: Gilead Sciences

• belapectin: Galectin Therapeutics Inc.

Discover more about therapies set to grab major Portal Hypertension market share @ Portal Hypertension Treatment Market

Scope of the Portal Hypertension Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Portal Hypertension Companies: Boehringer Ingelheim, Galectin Therapeutics Inc., Onyx Therapeutics, Inc., Novartis, Cumberland Pharma, Conatus Pharma, Ferozsons Laboratories Ltd., Histogen, Gilead Sciences, Galectin Therapeutics Inc., and others

• Key Portal Hypertension Therapies: BI 685509, GR-MD-02, Sorafenib, Serelaxin, Ifetroban, IDN-6556, Terlipressin, Emricasan, Ambrisentan, belapectin, and others

• Portal Hypertension Therapeutic Assessment: Portal Hypertension current marketed and Portal Hypertension emerging therapies

• Portal Hypertension Market Dynamics: Portal Hypertension market drivers and Portal Hypertension market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Portal Hypertension Unmet Needs, KOL’s views, Analyst’s views, Portal Hypertension Market Access and Reimbursement

To know more about Portal Hypertension companies working in the treatment market, visit @ Portal Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents

1. Portal Hypertension Market Report Introduction

2. Executive Summary for Portal Hypertension

3. SWOT analysis of Portal Hypertension

4. Portal Hypertension Patient Share (%) Overview at a Glance

5. Portal Hypertension Market Overview at a Glance

6. Portal Hypertension Disease Background and Overview

7. Portal Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Portal Hypertension

9. Portal Hypertension Current Treatment and Medical Practices

10. Portal Hypertension Unmet Needs

11. Portal Hypertension Emerging Therapies

12. Portal Hypertension Market Outlook

13. Country-Wise Portal Hypertension Market Analysis (2019–2032)

14. Portal Hypertension Market Access and Reimbursement of Therapies

15. Portal Hypertension Market Drivers

16. Portal Hypertension Market Barriers

17. Portal Hypertension Appendix

18. Portal Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Portal Hypertension Market Growth Projections 2023-2032: DelveInsight Analysis | Boehringer Ingelheim, Gilead Sciences, Novartis, Cumberland Pharma, Conatus, Onyx Therapeutics, Inc.

DelveInsight’s “Natural Killer (NK)-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma, historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Natural Killer (NK)-Cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Natural Killer (NK)-Cell Lymphoma Market Forecast

Some of the key facts of the Natural Killer (NK)-Cell Lymphoma Market Report:

• The Natural Killer (NK)-Cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In December 2024, Indapta Therapeutics, Inc., a private clinical-stage biotech firm focused on advanced cell therapies for cancer and autoimmune diseases, announced the closing of a $22.5 million funding round to fast-track the clinical development of its unique allogeneic Natural Killer (NK) cell therapy. The financing was led by existing investors including RA Capital Management, LP, Leaps by Bayer (Bayer AG’s impact investment arm), Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy branch of the Multiple Myeloma Research Foundation.

• In October 2024, Immunotherapy leader ImmunityBio, Inc. (NASDAQ: IBRX) announced the dosing of the first patients in an initial trial evaluating its CAR-NK cell therapy targeting CD19 for treating non-Hodgkin’s lymphoma (NHL). In the QUILT 106 study, CD19-targeted high-affinity natural killer (t-haNK) cells are initially tested as a single treatment and, after confirming safety, combined with the standard NHL therapy rituximab in patients with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. This Phase 1, open-label trial plans to enroll up to 10 participants and is underway in Johannesburg, Pretoria, and Bloemfontein, South Africa.

• In October 2024, ImmunityBio announced that the first patients have been treated in an early trial investigating the potential of the company’s CAR-NK cell therapy targeting CD-19 for non-Hodgkin’s lymphoma (NHL).

• In July 2024, The U.S. Food and Drug Administration (FDA) has approved Nkarta to initiate a clinical trial evaluating its cell therapy candidate NKX019 in patients with ANCA-associated vasculitis (AAV) and other autoimmune diseases.

• The increased utilization of NK cells in addressing cancer, infections, and liver diseases significantly contributes to the expansion of the market for Natural Killer Cells therapeutics.

• Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

• Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

Natural Killer (NK)-Cell Lymphoma Overview

Natural Killer (NK)-Cell Lymphoma is a rare and aggressive type of non-Hodgkin lymphoma that arises from natural killer cells, a type of immune cell. It most commonly affects the nasal area and upper respiratory tract but can also spread to other organs. NK-cell lymphoma is often associated with the Epstein-Barr virus (EBV) and is more prevalent in Asian and Latin American populations. Symptoms may include nasal obstruction, bleeding, fever, and weight loss. Due to its aggressive nature, early diagnosis and treatment—typically involving chemotherapy and radiation—are crucial for better outcomes.

Request a sample for the Natural Killer (NK)-Cell Lymphoma Market Report:

https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-market

Natural Killer (NK)-Cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidemiology Segmentation of Natural Killer (NK)-Cell Lymphoma:

• Prevalent Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019-2032]

• Age-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

• Gender-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

• Diagnosed and Treated Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

Download the report to understand which factors are driving Natural Killer (NK)-Cell Lymphoma epidemiology trends @ Natural Killer (NK)-Cell Lymphoma Epidemiology Forecast

Natural Killer (NK)-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Natural Killer (NK)-Cell Lymphoma market or expected to get launched during the study period. The analysis covers Natural Killer (NK)-Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Natural Killer (NK)-Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Natural Killer (NK)-Cell Lymphoma Pipeline Therapies

• Monalizumab: Innate Pharma

• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

• ALT 803: ImmunityBio

• ALECSAT: CytoVac

• PNK-007: Celularity

Discover more about therapies set to grab major Natural Killer (NK)-Cell Lymphoma market share @ Natural Killer (NK)-Cell Lymphoma Medications

Scope of the Natural Killer (NK)-Cell Lymphoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

• Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

• Natural Killer (NK)-Cell Lymphoma Therapeutic Assessment: Natural Killer (NK)-Cell Lymphoma current marketed and Natural Killer (NK)-Cell Lymphoma emerging therapies

• Natural Killer (NK)-Cell Lymphoma Market Dynamics: Natural Killer (NK)-Cell Lymphoma market drivers and Natural Killer (NK)-Cell Lymphoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Natural Killer (NK)-Cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement

To know more about Natural Killer (NK)-Cell Lymphoma companies working in the treatment market, visit @ Natural Killer (NK)-Cell Lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Natural Killer (NK)-Cell Lymphoma Market Report Introduction

2. Executive Summary for Natural Killer (NK)-Cell Lymphoma

3. SWOT analysis of Natural Killer (NK)-Cell Lymphoma

4. Natural Killer (NK)-Cell Lymphoma Patient Share (%) Overview at a Glance

5. Natural Killer (NK)-Cell Lymphoma Market Overview at a Glance

6. Natural Killer (NK)-Cell Lymphoma Disease Background and Overview

7. Natural Killer (NK)-Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Natural Killer (NK)-Cell Lymphoma

9. Natural Killer (NK)-Cell Lymphoma Current Treatment and Medical Practices

10. Natural Killer (NK)-Cell Lymphoma Unmet Needs

11. Natural Killer (NK)-Cell Lymphoma Emerging Therapies

12. Natural Killer (NK)-Cell Lymphoma Market Outlook

13. Country-Wise Natural Killer (NK)-Cell Lymphoma Market Analysis (2019–2032)

14. Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement of Therapies

15. Natural Killer (NK)-Cell Lymphoma Market drivers

16. Natural Killer (NK)-Cell Lymphoma Market barriers

17. Natural Killer (NK)-Cell Lymphoma Appendix

18. Natural Killer (NK)-Cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity